Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Genipin is a naturally occurring iridoid monoterpenoid aglycone derived from the hydrolysis of geniposide found in the fruit of *Gardenia jasminoides* and *Genipa americana*[1][3][6][9]. It is best known as a natural cross-linking agent for proteins such as collagen and gelatin due to its low toxicity compared to synthetic alternatives like glutaraldehyde[1][2][3][5]. Genipin has demonstrated diverse pharmacological activities including anti-inflammatory, antioxidative, neuroprotective, neurotrophic effects[3], choleretic action (promoting bile secretion)[6], and inhibition of lipid peroxidation and nitric oxide production[6]. Mechanistically, genipin inhibits mitochondrial uncoupling proteins UCP2 (and also UCP1/UCP3), thereby affecting mitochondrial proton transport and energy metabolism[2][6]. It has been used in traditional Chinese medicine for various indications such as inflammation reduction and liver disease. Genipin-cross-linked hydrogels are widely researched for drug delivery applications due to their biocompatibility and biodegradability[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on genipin.